CARTRIDGE FOR NEEDLE-FREE INJECTION DEVICE

Abstract

Cartridge (1) for a needle-free injection device (100) comprising: - at least one first chamber (5) containing and / or intended to receive a composition (C) to be injected, - at least one injection nozzle (6) communicating with the or each first chamber (5), the cartridge comprising several first chambers (5) and / or the cartridge comprising at least one second chamber (7) containing the composition (C) to be injected and communicating with the or each first chamber (5) via at least one supply conduit (8) through which the supply of the or each first chamber (5) with the composition (C) contained in the or each second chamber (7) is carried out.

Description

The present invention relates to a cartridge for a needle-free injection device, a needle-free injection system and a method for processing, particularly cosmetic, human keratinous materials. State of the art US publications 8876758 B2, US 9186461 B2, US 8066661 B2, US 20160129191 A1, US 8734384 B2 and US 9265888 B2 disclose needle-free injectors comprising a reservoir containing a gas, a chamber containing a piston and a viscous liquid formulation to be injected, the chamber communicating with an injection nozzle. Such needle-free injectors require, once the chamber is empty, its replacement or recharging, including manual recharging, in order to be usable again. Such needle-free injectors have an injection nozzle with fixed geometry and dimensions, which limits the formulations that can be used, particularly in terms of viscosity. This can lead to limitations on the treatments that can be performed and to formulation loss at the start of the injection. For example, to treat wrinkles, different products are currently available on the market, such as hyaluronic acid or Botox, which have different rheologies. Therefore, the same needle-free injector as described above cannot inject both products; the geometry and dimensions of the injection nozzle, particularly the size of its outlet, must be adapted to the product being injected. There therefore remains a need to further improve the injection of a product into human keratinous materials by a needle-free injector, in particular to prevent, treat and / or reduce a relief and / or a fold of a skin area and / or a skin colour disorder. Summary of the invention The present invention aims to further improve devices used to process human keratinous materials such as skin, and in particular to address the following: the above drawback. It achieves this thanks to a cartridge for a needle-free injection device, comprising: at least one first chamber containing and / or intended to receive a composition to inject, at least one injection nozzle communicating with the first chamber or each first chamber, the cartridge having several first chambers and / or the cartridge having at least one second chamber containing the composition to be injected and communicating with the first chamber or chambers by at least one supply conduit through which the first chamber or chambers are supplied with the composition contained in the second chamber or each second chamber. By "needle-free injection device" we mean a device in which the injection is carried out without penetration through the epidermis by an injection needle. In one embodiment of the invention, the cartridge comprises a first chamber for receiving the injection composition, an injection nozzle communicating with the first chamber, and at least one second chamber containing the injection composition and communicating with the first chamber via at least one feed channel through which the composition contained in the second chamber is supplied to the first chamber. With a nozzle having multiple outlet channels, the arrangement of the outlet channels can follow the shape of the area to be treated, for example, the shape of a wrinkle to be filled or a blemish to be treated. In one variant, the cartridge has several first chambers, each containing a composition to be injected, and at least one injection nozzle communicating with each first chamber. In another variant, the cartridge has several first chambers, each containing and / or intended to receive a composition to be injected, at least one injection nozzle communicating with each first chamber, and at least one second chamber containing the composition to be injected and communicating with the first chambers by at least one supply conduit, through which the first chambers are supplied with the composition contained in the second chamber. In the presence of several first chambers, the outlet channels of the corresponding nozzles can follow, as in the case of a single first chamber, the shape of an area to be treated, for example a wrinkle. The invention offers an easy-to-use, reliable, robust, compact and ergonomic solution for needle-free injection of a composition. The cartridge according to the invention has the advantage of being ready for use and requires no adjustment by the user before use. Its geometry and dimensions can be specifically designed for a particular application. For example, the geometry and dimensions of the first and second chambers and the injection nozzle are adapted to the volume and nature of the composition to be injected, including its rheology, in order to perform a given treatment. The second chamber(s) can serve as a multi-dose reservoir for the injectable composition. The second chamber(s) can also contain enough of the injectable composition to complete a full treatment session with multiple injections. After injecting a dose of the composition contained in the first chamber, the chamber can be automatically recharged with the composition contained in the second chamber(s), without the need to replace the cartridge. This reduces handling during treatment. By "skin," we mean the dermis and epidermis and the superficial region of the mucous membranes such as the lips The cartridge may contain several secondary chambers. Each secondary chamber may communicate with the first chamber(s) via at least one feed conduit. The secondary chambers may be arranged all around the first chamber. Preferably, especially when the composition is pressurized in the first chamber for injection, the feed line(s) include a shut-off valve, such as a ball. This valve can close the feed line during injection. Preferably, the obturator is kept closed by pressure in the first chamber during injection and opens between two injections to allow the first chamber to be filled with the composition contained in the second chamber(s). The cartridge can be supplied to the user with the first chamber(s) pre-filled or not with a unit dose of the composition to be injected. The pressurization of the first chamber(s) can be carried out in various ways. ways. Preferably, the first chamber receives a first piston connected to a push rod, the first piston sliding along the longitudinal axis of the first chamber, driven by the push rod. The pressure exerted on this first piston during injection is sufficient to force the composition out of the cartridge. This pressure is particularly sufficient to cause the composition to penetrate the skin, at least partially. Preferably, the injection nozzle forms the distal end of the cartridge. The nozzle has at least one outlet channel, each outlet channel having an opening through which the composition to be injected is expelled outwards. Preferably, the first chamber, the second chamber, the injection nozzle, and the feed duct are defined, at least partially, by a single-piece body. Such a one-piece construction can offer increased strength and is simpler to handle and use. Preferably, the volume V1 of the first chamber is smaller than that V2 of the second chamber. This allows the first chamber to be repeatedly filled or refilled with the composition contained in the second chamber, thus enabling multiple injections with the same cartridge. During an injection, all or part of the contents of the first chamber can be delivered to the user. In other words, the first chamber can be emptied in one go during the injection, or alternatively, several injections can be performed with the contents of the first chamber before refilling it with product, if necessary. The first chamber may be tubular in shape. Its wall may converge at its distal end, notably to the outlet channel of the injection nozzle. The second chamber can be annular in shape and extend around the first. This results in a compact construction, and communication between the two chambers can be achieved simply via a radial feed duct. Preferably, the second chamber(s) is closed at one of its axial ends by a second piston, particularly of annular shape, sliding along the axis longitudinal of the second chamber(s). This second piston can be pushed towards the distal end of the second chamber(s) to empty it. The pressure can be applied continuously, by a spring for example, or only when the first chamber is filling. The cartridge may include a third chamber located in line with the injection nozzle. This third chamber may be subjected to a pressure lower than atmospheric pressure. This increases the speed at which the composition is ejected from the nozzle towards the skin during injection, allowing the composition to penetrate the skin at least partially. The composition may have various formulations and rheologies depending on the purpose continued. Preferably, the composition is liquid and comprises a liquid phase, a mixture of a liquid phase and a powder phase and / or a mixture of a liquid phase and a gaseous phase. The liquid composition may have a viscosity greater than or equal to 10 Pa.s at 25°C and under atmospheric pressure. The composition may be intended for the treatment and / or prevention of wrinkles, and may include at least one filler, including a biopolymer such as hyaluronic acid and / or one of its salts, hydroxyapatite particles, polylactic acid, an alginate, sodium monomethyltrisilanol orthohydroxy benzoate, collagen, an acrylic polymer such as polyacrilamide, a methacrylic polymer and / or dextran microbubbles. The composition may include a liquid medium with particles in a dispersed state in the liquid medium, being solidifiable via the aggregation of said particles. Preferably, the composition comprises at least one biopolymer, in particular an alginate, and an ionic solution, in particular a solution of a divalent ion. The invention can help combat the skin signs of aging and in particular maintain and / or restore the viscoelastic or biomechanical properties of the skin, in order to improve the firmness, elasticity, tone of the skin and prevent the appearance of skin signs of aging. For the purposes of this invention, "viscoelastic or biomechanical properties of the skin" means the extensibility, tone, firmness, suppleness and / or elasticity of the skin. The term "cutaneous signs of aging" refers to all changes in the external appearance of the skin due to aging, whether chronobiological and / or extrinsic, primarily photo-induced, such as wrinkles and fine lines, sagging skin, loose skin, thinning skin, dull and lackluster skin, and a lack of skin elasticity and / or tone. Alternatively, the invention is used to prevent, treat, and / or reduce skin discoloration. In examples of implementations of the invention, the composition is thus a skin-coloring composition comprising at least one coloring agent. Preferably, the composition is cosmetic, but alternatively it exerts an action dermatological. The invention also relates, according to another of its aspects, to a needle-free injection system comprising a removable cartridge according to the invention, as defined above, and a needle-free injection device configured to receive said cartridge. The cartridge can be arranged to fit into a housing in the injection device. Alternatively, the cartridge is configured to be attached removably, for example by screwing or bayonet fitting, to the injection device. This allows the user to easily change the cartridge depending on its needs. Preferably, the injection device includes a first actuator to act on the push rod received in the first chamber of the cartridge. The device may include at least one second actuator, in particular of annular shape, to act on the second piston closing one of the ends of the second chamber. Preferably, the actuators enabling the emptying of the first and second chambers are moved along the longitudinal axis of the device towards the nozzle by drive means such as a source of compressed and / or liquefied gas. Alternatively, these actuators are moved along the longitudinal axis of the device towards the nozzle by other drive means such as a spring, a motor or an electromagnet. Preferably, the device includes at least one elastic return element to accompany or dampen the movement of the first piston in the first chamber and / or to help the latter return to its initial position after injection. The needle-free injection system according to the invention may include an automatic treatment area recognition system, configured to automatically determine the location and depth of the area to be treated when the injection system is brought close to the skin, and automatically adjust the injection parameters, including the injection depth. This system may generate information on the cartridge to use and / or the pressure to apply using the aforementioned drive means, so as to achieve the desired skin penetration. The invention also relates, according to another aspect, to a treatment process, particularly for cosmetic purposes (i.e., non-therapeutic), of human keratinous materials, comprising the steps of: to place a cartridge containing a composition to be injected into a device needle-free injection so as to form a needle-free injection system according to the invention as defined above, approaching the needle-free injection system for human keratinous materials to to treat, to deliver, with each injection into said human keratinous materials, a quantity of the composition contained in the cartridge. The process according to the invention may include the step of recharging the first chamber between two injections with a dose of composition taken from the second chamber of the cartridge. The invention allows, in particular, the injection of the composition into the epidermis and / or the dermis. To control the injection depth, one can adjust the pressure in the first chamber and the speed at which the composition is ejected from the nozzle towards the skin. The invention also relates, according to another of its aspects, to the cosmetic, i.e. non-therapeutic use of a needle-free injection system according to the invention as defined above, for the improvement of the appearance, in particular the aesthetic appearance, of the skin. In particular, the needle-free injection system according to the invention can be used to prevent, treat and / or reduce a relief and / or fold of a skin area, including a fine line, wrinkle and / or scar. Composition The composition to be injected according to the invention is preferably liquid, at least at moment of its injection. The composition can be a liquid phase, a mixture of a liquid phase and a powdered phase, a mixture of a liquid phase and a gaseous phase, or a liquid, powdered and gaseous phase. Viscosity is measured at 25 °C and under 1 atm, with a Rhéomat 180 viscometer equipped with the MK-R-1, 2 or 3 mobile depending on the viscosity range and the corresponding MB-R-1, 2 or 3 measuring cup, at a rotation speed of 200 min', the measurement being carried out after 10 minutes of rotation (time after which a stabilization of the viscosity and the rotation speed of the mobile is observed). The composition may have a viscosity greater than or equal to 10 Pa.s, at the time of his injection. The composition according to the invention may include an oil phase. The oil phase may, in particular, include oils, waxes, or pasty fats. "Pasty fat" refers to a viscous product containing a liquid fraction and a solid fraction. Specifically, it refers to fats having a melting point of 20 to 55°C and / or a viscosity at 40°C of 0.1 to 40 Pa·s (1 to 400 poises) measured using Contraves TV or Rhéomat 180. The composition according to the invention may include an aqueous phase. Preferably, the composition to be injected is sterile and biocompatible. The composition to be injected may be a cosmetic composition, in which case it includes a physiologically acceptable medium, that is to say a non-toxic medium suitable for injection into the skin of human beings. The injectable composition can still be dermatological. Composition to treat and / or prevent a raised area and / or a fold in the skin Filling agents As mentioned above, the composition according to the invention may include minus a filler. A composition containing at least one filler may or may not exhibit the same rheology before and after injection into the skin. In particular, the composition may be more fluid at the time of injection and solidify or become more viscous in situ. Preferably, the filler contains at least one biopolymer. Because of the mechanism of action of biopolymers and their injection, thanks to the invention, into quantities and depths within the skin that cannot be achieved by the use of topical compositions, lasting and visible effects can be obtained. Dermal fillers can be absorbable or semi-absorbable. "Absorbable" refers to a filler that dissolves completely within the skin in 3 to 6 months, while "semi-absorbable" refers to a filler that dissolves completely within the skin in 6 to 24 months. These timeframes correspond to the duration of the filler's effect. Alternatively, the filler may be non-absorbable. The composition according to the invention may comprise at least one filler such as hyaluronic acid and / or one of its derivatives and / or one of its salts. Preferably, hyaluronic acid is cross-linked. Cross-linking creates a rigid, elastic, cross-linked gel that hydrates and swells in water. Cross-linked hyaluronic acid is used for its filling properties, particularly for fine lines and / or wrinkles, due to the gel's rigidity, as well as its highly viscoelastic properties and high hydrating capacity. Hyaluronic acid can notably be used in mixture with lidocaine and / or dextran microbubbles. The composition to be injected can be a solution from the BELOTERO® range marketed by the company Merz, in particular the BELOTERO® Soft solution. The composition according to the invention may comprise hydroxyapatite particles, in particular calcium, polylactic acid, an alginate, monomethyltrisilano! sodium orthohydroxy benzoate, collagen, an acrylic polymer such as polyacrylamide, a methacrylic polymer, and any mixture of the above compounds. Agents with variable rheology The injectable composition according to the invention may be a composition comprising at least one agent with variable rheology. The viscosity of this composition then increases between the time the composition is prepared and a time after injection, after it has reached its target site in the skin. The increase in viscosity can occur through gelation or any other physical phenomenon causing particles or molecules of the composition to agglomerate, for example under the effect of electrostatic forces or coalescence, which leads to the creation of a kind of network or mesh. The aggregation process can be triggered by heat, when the temperature of the composition rises above a certain value, preferably close to 37°C. Thus, the composition, when injected, may have a lower viscosity than it subsequently achieves in situ within the skin at the injection site. Its injection is facilitated without compromising its performance in filling skin imperfections. The composition may be a liquid composition containing particles dispersed in a liquid medium, said composition being able to solidify by the aggregation of particles. The composition may include at least one biopolymer, preferably an alginate, and an ionic solution, particularly a divalent ionic solution. The viscosity of the biopolymer advantageously increases in the skin through gelation until it solidifies. Due to the biopolymer's aggregation mechanism and its injection into the skin in quantities and at depths unattainable with topical compositions, long-lasting and visible effects can be achieved. One of the biopolymers considered according to the invention may be Novabel® alginate from the company Merz, which is resorbable in 3 to 6 months. In a preferred embodiment, the composition comprises a sodium alginate and a solution of a calcium salt, preferably a calcium carbonate (CaCO₃) solution. The enhanced reactivity of alginates with calcium ions was described in the article From B. Larsen et al. "Rheological characterization of an injectable alginate gel system", BMC Biotechnology 2015, pages 15-29, A solution of active compounds, such as a calcium carbonate solution, allows, by ionic energy transport, the in situ generation of a precipitate forming a film or a lattice in the layers of the skin. A particularly suitable sodium alginate is derived from brown algae and can be an FMC® injectable polymer powder solubilized in water. Such a compound is a hydrophilic colloid, or hydrocolloid, defined as a colloidal system in which the colloidal particles are hydrophilic polymers dispersed in water. The biopolymer and the ion solution can be mixed before packaging in the cartridge. Alternatively, the biopolymer and the ion solution are contained in separate reservoirs and injected separately and sequentially. Aggregation of the composition is advantageously triggered by heat once injected into the skin. The composition can be absorbable, semi-absorbable or non-absorbable. Composition for treating and / or preventing a skin discoloration disorder Skin coloring agents The composition according to the invention may be a composition comprising at least one skin coloring agent. The coloring agent may be melanin. The coloring agent can be chosen from pigments, including interference pigments, and dyes, including water-soluble or fat-soluble dyes. The presence of at least one skin-coloring agent in the composition makes it possible to correct a color disorder or to create long-lasting or permanent makeup. The pigments useful in the present invention may be in the form of pigment powder or paste. By "colorants", we mean compounds, generally organic, soluble in at least one oil, in a hydroalcoholic phase or in water. By "pigments" we mean white or colored particles, mineral, organic or mineral / organic composite, insoluble in an aqueous or oily medium, intended to color and / or opacify. By "interference pigments" we mean colored particles of any shape, iridescent or not, preferably synthesized and which exhibit a color effect by optical interference, for example a Mica / TiO pigment, i.e. a mica particle covered with a layer of titanium oxide TiO of controlled thickness. The composition may include an aqueous phase and at least one pigment, in particular chosen from mineral or organic pigments, and in particular from non-lamellar mineral pigments. The aqueous phase can represent at least 50% of the total weight of the composition. Preferably, the pigment is a pigment approved by the CTFA for use in cosmetics and by the FDA for use in cosmetic formulations. Metallic oxides such as iron oxides (especially those of yellow, red, brown, and black color), titanium dioxides, aluminum oxide, zinc oxide, cerium oxide, zirconium oxide, chromium oxide, composite oxides, manganese violet, ultramarine blue, Prussian blue, ultramarine blue, iron blue, and mixtures thereof can be used as pigments. In one variant, the pigment used is an organic pigment chosen from synthetic or natural pigments, in particular from FD&C and D&C pigments. The organic pigment may also be a diketopyrrolopyrrole (DPP) as described in publications EP-A-542669, EP-A-787730, EP-A-787731 and WO-A-96 / 08537. The composition is for example one of the BioChromaDerm® or BioChromaEyes® bio-pigment solutions from the company Biotic Phocea. The composition may include a fat-soluble or water-soluble colorant. For example, fat-soluble dyes are chosen from Sudan Red, DC Red 17, DC Green 6, beta-carotene, soybean oil, Sudan Brown, DC Yellow 11, DC Violet 2, DC Orange 5, quinoline yellow, and mixtures thereof. Water-soluble dyes are chosen, for example, from beetroot juice and methylene blue and mixtures thereof. The composition may also include high refractive index fillers or reflective particles or particles that modify the path of light to prevent reflection. The composition may include, in particular, at least one chosen coloring agent among (and their mixtures): Additives The composition according to the invention may include at least one common cosmetic ingredient other than a filler or a coloring agent, which may be chosen in particular from antioxidants, sunscreens, vitamins, moisturizers, anti-wrinkle agents, emollients, hydrophilic or lipophilic agents, free radical scavengers and mixtures thereof. In the long term, injecting the composition into human keratin tissue can stimulate the user's own collagen production by collagen-producing cells. Lasting effects can thus be observed, including the filling of fine lines and / or wrinkles. The invention will be better understood upon reading the detailed description that follows, a non-limiting example of its implementation, and upon examination of the attached drawing, in which: Figure 1 schematically and in perspective represents an example of cartridge according to the invention, Figure 2 is a longitudinal section in plane A of Figure 1. Figure 3 represents a longitudinal section in plane A of Figure 1. without the push rod, Figure 4 schematically and in perspective represents an example of an injection system according to the invention, Figure 5 is a longitudinal section along plane B of Figure 4. Figure 6 schematically represents an example of a system injection according to the invention, and Figure 7 shows a detail of a variant of the cartouche in elevation. Cartridge Figure 1 shows an example of a cartridge 1 for an injection device without a needle according to the invention. The cartridge 1 generally extends along an X axis. It comprises a body 2 having a cylindrical portion 2a having at one end 3 an opening 3a. The cylindrical portion 2a extends opposite the end 3 by a frustoconical portion 2b forming an injection nozzle 6. The cartridge 1 is configured to be mounted on an injection device, not apparent in figure 1. The injection nozzle 6 has an outlet channel 6a and an end face 6b to be positioned opposite or in contact with the human keratinous materials to be treated. As shown in Figure 2, the cartridge 1 has a first chamber 5 for receiving the composition C to be injected. The channel 6a of the injection nozzle 6 communicates with this first chamber 5. A second chamber 7, containing a composition reserve, communicates with the first chamber S by at least one supply conduit 8. In the illustrated example, the first chamber 5 occupies a central position in the cartridge 1, and has a first cylindrical portion 5a, with a cross-section S1, and a second cylindrical portion Sc, with a cross-section S2, smaller than the cross-section S1. The first and second portions Sa and Sc are connected by an intermediate portion Sb converging towards the distal end of the cartridge 1. The first chamber S has a distal portion 5d whose wall converges towards the distal end of the cartridge 1, this portion 5d forming the bottom of the first chamber 5. The latter may have, as illustrated, a circular cross-section along its entire length. The output channel 6a can have a constant cross-section, for example circular, along its entire length. Alternatively, the injection nozzle 6 has several outlet channels 6a, each connected to the bottom Sd of the first chamber 5 and each opening at the end of the nozzle through a corresponding opening 6c. The opening 6c of the outlet channel(s) 6a of the injection nozzle 6 can be covered before first use with a removable cap (not shown), which adheres at the end of the injection nozzle 6. This seal ensures the preservation and sterility of composition C contained in cartridge 1. The first chamber 5 receives a first piston 9 whose distal end 9a has a conical shape, complementary to that of the bottom Sd of the first chamber 5. This first piston 9 can be made of an elastomeric material. The first piston 9 applies itself in a sealing manner against the internal surface of the portion Sc of the first chamber 5, and may include one or more annular sealing lips, for example as illustrated two lips 9b and 9c. The cartridge 1 may include a push rod 10 whose distal end 10a is fixed by snap-fit, screw-fit, friction and / or any other means on the first piston 9. The rod 10 has at its proximal end a head 10b configured to cooperate with a drive system of the injection device. The cartridge 1 is arranged so that the first piston 9 slides within the first chamber 5, along its longitudinal axis, driven by the push rod 10. Alternatively, the cartridge 1 does not have a first piston 9 or a push rod 10, as illustrated in Figure 3. The first piston 9 can then be fixed to the distal end 10a of the push rod 10. The opening of the first chamber 5 at the proximal end 3 of the cartridge 1 can be covered before first use with a removable cap (not shown) which adheres to the proximal end 3 of the cartridge 1. This cap ensures the preservation and sterility of the composition C contained in the cartridge 1. The second chamber 7 can be annular in shape and extend around the first chamber S, as illustrated. Preferably, the volume of the second chamber 7 is greater than that of the first chamber 5. The second chamber 7 communicates with the first chamber 5 via a supply conduit 8. The latter can be perpendicular to the axis of chamber 5, as illustrated, or oblique upwards or downwards. This conduit 8 is equipped with a valve 11 which opens in the direction of a circulation of the composition from the second chamber 7 to the first S. This valve does not have a spring to return the obturator 12, here constituted by a ball, to rest. Alternatively, the second chamber 7 communicates with the first chamber S via several supply conduits 8. This allows for better transfer of the composition from the second chamber 7 to the first chamber 5, including faster transfer. The second chamber 7 is closed at one end by a second piston 14, which in the example considered is annular in shape. This second piston 14 is applied in a tight seal against the inner wall 7a of the second chamber 7. It may have one or more sealing lips 14a and 14b. The second piston 14 can be driven by any means in the direction of emptying. the second chamber 7. The first chamber 5, the second chamber 7, the injection nozzle 6, and the feed duct 8 can be formed as a single piece. Alternatively, they are formed by assembling several components. The cartridge 1 can be made of a thermoplastic material, in particular polycarbonate. The elements of the cartridge 1 in contact with the composition C to be injected, in particular the wall of the first chamber 5, the second chamber 7, the supply conduit 8 and the outlet channel 6a, can be coated with glass, in particular silicone-coated and / or depyrogenated. In one variant, if the viscosity of the composition allows, the radially outer wall 20 of the cartridge 1 is made of a flexible, deformable material. This then allows the user to supply the first chamber S with the composition C contained in the second chamber 7 by applying pressure to the wall 20, for example with their fingers. In another variant, the cartridge includes a visual indicator of the degree of emptying of composition C contained in the second chamber 7, for example a transparent window made in the wall 20. The cartridge can be specifically designed for a particular application, such as the treatment and / or prevention of skin surface wrinkles, for example, nasolabial folds (also known as labio-nasal folds), crow's feet, the area between the eyebrows, and / or the forehead. The cartridge can also be designed for use on fine lines, superficial wrinkles, and / or deep wrinkles. The nature of the active compound present in the composition to be injected, the volumes and dimensions of the first and second chambers and the injection nozzle are adapted to the intended application and the physico-chemical properties of the composition, such as particle size when the composition is a loose powder or viscosity when the composition is a liquid. Alternatively, the cartridge 1 has several second chambers. Each second chamber communicates with the first chamber via at least one supply channel. Each second chamber may be tubular in shape and located outside the first chamber, its proximal end closed by a corresponding second piston. These second chambers may all contain the same composition C to be injected. Alternatively, the second chambers contain different compositions. This allows the same cartridge 1 to be used in several applications. If applicable, at least one of the second chambers contains a cleaning agent in place of a composition C to be injected. This allows the cartridge 1, in particular the injection nozzle 6, to be cleaned between two injections of different compositions.The cleaning solution can be chosen from among the solvents in the composition to be injected, ensuring compatibility, and may contain isodecane, volatile silicone, alcohol, or water. The cartridge can be removable and replaceable. The cartridge may or may not be refillable. The cartridge may include means for heating the composition C to be injected or the area of ​​human keratinous material to be treated. The cross-section and radius of curvature of the end face 6b of the injection nozzle 6 are selected, where appropriate, according to the type of keratinous material being treated, with face 6b then being applied directly to the treated keratinous material. The radius of curvature can be chosen to closely follow the curvature of the treated area. This facilitates the application of the injection system to certain body surfaces. For example, face 6b has an outwardly concave shape. Several cartridges 1 with nozzles of different shapes can be offered to the user for mounting on the injection device. This allows the selection of a cartridge 1 with the injection nozzle shape best suited to the area of ​​keratinous material to be treated. In an unillustrated variant, the cartridge has several first chambers 5 equipped with their respective pistons, so as to allow several injections in parallel, simultaneously, or sequentially. These first chambers can be supplied by the same second chamber, or by separate second chambers. The entire preceding description of an embodiment with only one first chamber 5 also applies to a variant with multiple first chambers. As illustrated in Figure 7, the cartridge 1 may include a third chamber 60 arranged in line with the injection nozzle 6, in the path of the composition's dispensing. This third chamber 60 has an outlet orifice (not shown) through which the composition to be injected is expelled. This third chamber 60 may be subjected to a pressure lower than atmospheric pressure, for example by being connected to a vacuum source (not shown). This increases the velocity at which the composition is ejected from the nozzle towards the skin during injection, thus allowing the composition to penetrate the skin at least partially. Needle-free injection device The injection system 150 according to the invention, represented in particular in Figure 4, comprises the cartridge 1 according to the invention described above and an injection device 100. Cartridge 1 is configured to come into contact with, and in particular to be inserted into, the injection device 100. Cartridge 1 can be attached to the injection device 100 by any means. The injection device 100 may include a housing 101 made of a thermoplastic material, in particular polycarbonate-based. The 101 case can be given different shapes. Preferably, the 101 case has an elongated shape to facilitate handling and its manipulation. The housing 101 may include a first portion 10la which attaches to the cartridge 1 and a second portion 101b in line with the first, with a larger cross-section and a greater length than the first. As illustrated in Figure S, the first portion 101a of the housing 101 may have at its distal end a tip 104 configured to engage in the proximal portion Sa of the first chamber 5. The injection device 100 may include any propulsion means enabling the composition C contained in the cartridge 1 to be expelled outwards through the opening(s) 6c of the injection nozzle 6. This propulsion means can be operated by a gas, and include a first actuator 103 configured to slide within a housing 106 along the longitudinal axis of the injection device 100. The pressurized gas source can be a gas cartridge 102, received in a housing 105 of the second portion 101b of the housing 101. The gas cartridge 102 can be removable and / or rechargeable. As illustrated in Figure 6, the injection device 100 may include a regulation and control system 140 for the gas cartridge 102, comprising, for example, a solenoid valve and / or a pressure regulator. This control system 140 may allow the delivery of gas pulses. The control system 140 may allow the regulation of parameters such as pressure, flow rate, duration, and frequency of the gas pulses. The control system 140 can be electrically connected to a power supply 160. The role of the power supply 160 is to provide electrical energy to the control system so that it can operate. The power supply 160 can be a battery, including a rechargeable one, a mains power supply, or any other electrical power source. The gas cartridge 102 can drive the first actuator 103 to forcibly expel composition C contained in the first chamber 5 into the keratinous materials and, if necessary, drive the second actuator 109 to push the reserve of composition C contained in the second chamber 7 towards the first chamber 5 so as to recharge the latter. The gas used can be air, nitrogen, CO2, or any other propellant gas. Alternatively, the first actuator 103 is actuated by an electromagnet or a spring whose compression can be manual or motorized. The first actuator 103 may include, as illustrated in Figure 5, at least one elastic return member 111 configured to assist the movement of the first actuator 103 during injection or, on the contrary, to dampen this movement or to help the actuator return to its initial position after injection. The first actuator 103 has at its distal end a head 103a connected by a coupler 107 to the push rod 10, The injection device 100 may include a second actuator 109 configured to slide the second piston 14 within the second chamber 7 along the longitudinal axis of the injection device 100. This allows the first chamber 5 to be supplied with the composition C contained in the second chamber 7. The second actuator 109 can be actuated by a spring-loaded actuation mechanism 110. Alternatively, the second actuator 109 is driven by any other actuation means. For example, the second actuator 109 is actuated by a pressurized gas source, and in particular by the gas cartridge 102. The second actuator 109 can be annular in shape. The cartridge 1 may, in one variant, include several secondary chambers 7 arranged around the first chamber 5, each closed by a second piston at its proximal end. The cartridge 1 can be rotatably mounted on the injection device 100. Rotating the cartridge on the injection device aligns the second actuator 109 with one of the secondary chambers in a carousel-like arrangement. This rotation can be performed manually or by a motor. This allows the user to select which of the secondary chambers 7 feeds the first chamber 5. In another variant, the device includes several second actuators 109. The injection can be triggered by a user action on a control device such as a push button, for example. The 101 housing can therefore include a push button (not shown) which allows the user, by pressing it, to trigger the injection. The supply of the first chamber 5 from the composition reserve C contained in the second chamber 7 can also be carried out, if necessary, by means of a user-operable element. Device 100 can be offered to the user, with one or more cartridges 1 containing one or more compositions to be injected, for example within a common package, these cartridges being able to each have a nozzle specific to the type of treatment to be carried out. The 100 injection device can constitute a portable and autonomous system. The injection device 100 may optionally include a cartridge recognition system, for example, using an electromechanical sensor, electrical contacts, or an electronic chip. For example, cartridge 1 may contain an RFID chip that is read by the injection device 100. Cartridge 1 can thus be automatically recognized by the injection device 100. The device's knowledge of the cartridge in place allows for the automatic adjustment of operating parameters, such as the pressure, duration, flow rate, and / or frequency of the gas pulses exiting the cartridge. In one variant, the operation and / or settings of the 150 injection system are controlled remotely, for example with a smartphone. The 150 injection system then includes a wireless communication interface. The invention is not limited to the examples just described. For example, in one embodiment, the injection device does not include a first piston to pressurize the contents of the first chamber. The term "comprising" should be understood in its common sense, that is, as synonymous with "comprising at least one", unless otherwise specified.

Claims

CLAIMS 1. Cartridge (1) for needle-free injection device (100) comprising: - a first chamber (5) containing and / or intended to receive a composition (C) to be injected, - an injection nozzle (6) communicating with the first chamber (5), - a second chamber (7) containing the composition (C) to be injected and communicating with the first chamber (5) by at least one supply conduit (8) through which the first chamber (5) is supplied with the composition (C) contained in the second chamber (7), the second chamber (7) being annular in shape and extending around the first.

2. Cartridge according to claim 1, the or each supply duct (8) comprising a shutter (12), the latter closing the or each supply duct (8) during injection and opening it between two injections for filling the first chamber (5).

3. Cartridge according to any one of the preceding claims, the first chamber (5) receiving a first piston (9) connected to a push rod (10), the first piston (9) sliding along the longitudinal axis of the first chamber (5) while being driven by the push rod (10).

4. Cartridge according to any one of the preceding claims, the volume of the first chamber (5) being less than that of the second chamber (7).

5. Cartridge according to any one of the preceding claims, comprising a third chamber (60) arranged in the extension of the injection nozzle (6), this chamber being subjected to a pressure lower than atmospheric pressure.

6. Cartridge according to any one of the preceding claims, the second chamber (7) being closed at one of its ends by a second piston (14), in particular of annular shape, sliding along the longitudinal axis of the second chamber (7).

7. Cartridge according to any one of the preceding claims, the composition (C) being liquid and comprising a liquid phase, a mixture of a liquid phase and a powder phase, a mixture of a liquid phase and a gaseous phase, or a mixture of a liquid, powder and gaseous phase.

8. Cartridge according to claim 7, the composition (C) having, at least at the time of its injection, a viscosity greater than or equal to 10 Pa.s at 25°C and under atmospheric pressure.

9. Cartridge according to claim 7 or 8, the composition (C) comprising a dispersion of particles in a liquid medium, said composition being solidifiable via the aggregation of said particles.

10. Cartridge according to claim 9, the composition (C) comprising at least one biopolymer, in particular an alginate, and an ionic solution, in particular a solution of a divalent ion.

11. Cartridge according to any one of the preceding claims, the composition (C) comprising at least one filling agent, in particular a biopolymer such as hyaluronic acid and / or one of its salts, hydroxyapatite particles, polylactic acid, an alginate, sodium monomethyltrisilanol orthohydroxy benzoate, collagen, an acrylic polymer such as polyacrilamide, a methacrylic polymer and / or dextran microbubbles.

12. Cartridge according to any one of the preceding claims, the composition (C) comprising at least one skin coloring agent, in particular chosen from pigments, in particular interference pigments, and dyes, in particular water-soluble or liposoluble.

13. A needle-free injection system (150) comprising a cartridge (1) according to any one of the preceding claims, and a needle-free injection device (100) for actuating the cartridge (1).

14. Process for the cosmetic, non-therapeutic treatment of human keratin materials, comprising the steps of: - arranging a cartridge (1) containing a composition (C) to be injected into a needle-free injection device (100) so as to form a needle-free injection system (150) according to claim 13, - bring the needle-free injection system (150) close to the human keratin materials to be treated, - deliver at each injection into said human keratin materials, a quantity of the composition (C) contained in the cartridge (1).

Images